Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

EPRX Eupraxia Pharmaceuticals Inc

3,30

-0,1381 (-4,02%)

17 Déc 2024 - Fermé

Retardé de 15 minutes

Form D - Notice of Exempt Offering of Securities

Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024

Plus de graphiques de la Bourse Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024

Plus de graphiques de la Bourse Eupraxia Pharmaceuticals

Actualités Eupraxia Pharmaceuticals Inc

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mercredi 20 Novembre 2024 ( il y a 4 semaines) • Edgar (US Regulatory)

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Mercredi 20 Novembre 2024 ( il y a 4 semaines) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Jeudi 14 Novembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Jeudi 14 Novembre 2024 ( il y a 1 mois) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mercredi 13 Novembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Mercredi 13 Novembre 2024 ( il y a 1 mois) • PR Newswire (Canada)

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Mardi 12 Novembre 2024 ( il y a 1 mois) • PR Newswire (US)

Form D - Notice of Exempt Offering of Securities
Vendredi 8 Novembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Jeudi 7 Novembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
Jeudi 7 Novembre 2024 ( il y a 1 mois) • PR Newswire (US)

Form SC 13D - General Statement of Acquisition of Beneficial Ownership
Jeudi 7 Novembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
Vendredi 1 Novembre 2024 ( il y a 2 mois) • PR Newswire (US)

Plus d'articles sur Eupraxia Pharmaceuticals Inc

Cie de SaintGobain

Societe Generale

Credit Agricole

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales